Please ensure Javascript is enabled for purposes of website accessibility

Marijuana Gains Global Support With Approvals On The Horizon In Germany and Canada

By Todd Campbell - May 6, 2016 at 3:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Germany and Canada are among nations considering pro-pot laws in 2017.

Germany's top health regulator reported this week that the country will pass sweeping medical marijuana legislation that will allow Germans with illness access to the drug. Separately, momentum is building in Canada for pro-pot legislation that will allow for recreational use. Since these advances in the marijuana movement could influence decisions here in the U.S., let's learn more about what's going on.

Overcoming obstacles
Currently, Germans with AIDS can be prescribed marinol, a drug derived from the cannabinoid THC, and MS patients who suffer from muscle spasticity can be prescribed GW Pharmaceuticals' (GWPH) Sativex, a spray formulation of THC. Soon, many more patients who suffer from a variety of otherwise un-treatable ailments may also be able to get their prescriptions filled for dried marijuana buds.

According to Germany's Health Minister Hermann Grohe, legislation has been sent to Germany's parliament that would allow patients to purchase medical marijuana at pharmacies. That medical mariijuana would be grown at specially licensed plantations in Germany, and health insurance will be required to cover the cost of a prescription.

Germany's legislation doesn't go as far as recreational users might like, but it could help break down barriers that could lead to further reform later on. That's what happened already in the United States. Prior to passing their recreational marijuana laws, Colorado, Oregon, Washington, and Alaska all had medical marijuana laws on the books first. 

Germany's parliament could still say no to Grohe's legislation, but if they pass it, medical marijuana could become a reality in 2017.

North of the border
In Canada, it's already OK for people to use medical marijuana under licenses granted by Health Canada. That privilege could expand significantly next year if Health Minister Jane Philpott's plans pan out.

Philpott says that recreational marijuana legislation will be put forth early in 2017 that makes good on Prime Minister Justin Trudeau's promises to legalize the drug. In December, Trudeau reiterated his pro-pot stance in a speech to Canada's parliament.

At a special United Nations general assembly meeting on drugs recently, Philpott explained Canada's pro-pot position. By regulating the market, she believes they can keep marijuana out of the hands of children while also keeping criminals from profiting from the drug. Decriminalization will also reduce the burden that is put on prisons by enforcing the country's existing anti-marijuana laws.

Multiple fronts
The global grass-roots movement in support of marijuana legalization comes at the same time that drug developers are making strides in scientifically proving that marijuana can help patients.

Although the company suffered a high-profile disappointment when a study of THC in cancer pain failed in 2015, GW Pharmaceuticals reported earlier this year that its Epidiolex, a CBD derived medicine, significantly lowered the number of seizures experienced by people suffering from a form of epilepsy.

Specifically, GW Pharmaceuticals study showed that patients with Dravet syndrome who were treated with Epidiolex experienced 39% fewer seizures per month.

Increasing media coverage of scientific advances in the evaluation of marijuana as medicine may be helping tear down long-standing stereotypes. According to recent polls, Americans are more willing than ever to support marijuana legalization. Nationally, a poll conducted by Gallup revealed that 58% of Americans support legal marijuana. Similarly, polls in states considering approval, such as Florida, where medical marijuana is being considered, also tilt in favor of approval.

Looking ahead
There's considerable momentum to take a different approach to marijuana than has been taken in the past. An approval of medical marijuana in Germany and passage of recreational marijuana in Canada could further that momentum. If it does, then the global market for marijuana could look much different in a few years than it does today. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.